Illumina (NASDAQ:ILMN) Hits New 52-Week High on Better-Than-Expected Earnings

Illumina, Inc. (NASDAQ:ILMN)’s stock price hit a new 52-week high during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $199.65 and last traded at $197.1860, with a volume of 298140 shares changing hands. The stock had previously closed at $194.82.

The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 30.54% and a net margin of 18.36%.The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday. Citigroup upped their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Guggenheim lifted their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday. Finally, Royal Bank Of Canada lifted their target price on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $175.47.

Insider Activity at Illumina

In related news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 in the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Institutional investors have recently modified their holdings of the stock. Impact Partnership Wealth LLC increased its position in Illumina by 235.8% during the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after acquiring an additional 7,780 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in Illumina during the 1st quarter valued at $5,460,000. SG Americas Securities LLC grew its position in Illumina by 8.0% in the 1st quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company’s stock valued at $10,640,000 after acquiring an additional 6,425 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in shares of Illumina by 27.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company’s stock worth $45,645,000 after purchasing an additional 74,900 shares during the last quarter. Finally, New York State Teachers Retirement System increased its position in shares of Illumina by 2.7% during the fourth quarter. New York State Teachers Retirement System now owns 149,638 shares of the life sciences company’s stock worth $19,627,000 after acquiring an additional 4,002 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

The company has a market capitalization of $31.03 billion, a PE ratio of 38.26, a P/E/G ratio of 3.03 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a fifty day simple moving average of $176.70 and a 200 day simple moving average of $147.24.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.